Literature DB >> 32240526

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.

Tatsunori Shimoi1,2, Shigenori E Nagai3,2, Tetsuhiro Yoshinami4,2, Masato Takahashi5,2, Hitoshi Arioka6,2, Mikiya Ishihara7,2, Yuichiro Kikawa8,2, Kei Koizumi9,2, Naoto Kondo10,2, Yasuaki Sagara11,2, Masahiro Takada12,2, Toshimi Takano13,2, Junji Tsurutani14,2, Yoichi Naito15,2, Rikiya Nakamura16,2, Masaya Hattori17,2, Fimikata Hara18,2, Naoki Hayashi19,2, Toshiro Mizuno7,2, Minoru Miyashita20,2, Nami Yamashita21,2, Takashi Yamanaka22,2, Shigehira Saji23,2, Hiroji Iwata17,2, Tatsuya Toyama24,25.   

Abstract

PURPOSE: We present the English version of The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition.
METHODS: The JBCS formed a task force to update the JBCS Clinical Practice Guidelines, 2015 edition, according to Minds Handbook for Clinical Practice Guideline Development 2014. First, we set multiple outcomes for each clinical question (CQ). Next, quantitative or qualitative systematic review was conducted for each of the multiple outcomes, and the strength of recommendation for the CQ was taken into consideration during meetings, with the aim of finding a balance between benefit and harm. Finalized recommendations from each session were confirmed through discussion and voting at the recommendation decision meeting.
RESULTS: The recommendations, the strength of recommendation and the strength of evidence were determined based on systemic literature reviews and the meta-analyses for each CQ.
CONCLUSION: The JBCS updated the Clinical Practice Guidelines for systemic treatment of breast cancer.

Entities:  

Keywords:  Breast cancer; Guideline; Systemic treatment

Mesh:

Year:  2020        PMID: 32240526     DOI: 10.1007/s12282-020-01085-0

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  1 in total

Review 1.  Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

Authors:  Lorna Gibson; David Lawrence; Claire Dawson; Judith Bliss
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07
  1 in total
  12 in total

1.  The era of meta-analyses-based recommendations: how were the Japanese Breast Cancer Society Clinical Practice Guidelines for Systemic Treatment of Breast Cancer established?

Authors:  Toshimi Takano
Journal:  Breast Cancer       Date:  2020-05       Impact factor: 4.239

2.  Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).

Authors:  Shigehira Saji; Shozo Ohsumi; Mitsuya Ito; Naoki Hayashi; Kokoro Kobayashi; Norikazu Masuda; Naoki Niikura; Toshinari Yamashita; Keiichiro Kiyama; Ayumi Hasegawa; Shizuka Nakagawa; Masaya Hattori
Journal:  Jpn J Clin Oncol       Date:  2022-10-06       Impact factor: 2.925

Review 3.  Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer.

Authors:  Yuka Inoue; Makoto Fujishima; Makiko Ono; Jun Masuda; Yukinori Ozaki; Tetsuyo Maeda; Natsue Uehiro; Yoko Takahashi; Takayuki Kobayashi; Takehiko Sakai; Tomo Osako; Takayuki Ueno; Shinji Ohno
Journal:  Breast Cancer Res Treat       Date:  2022-09-24       Impact factor: 4.624

4.  Effect of Bevacizumab on a Human Breast Cancer Model that Exhibited Palbociclib-resistance by RB Knockout.

Authors:  Nobuyuki Ishikura; Masamichi Sugimoto; Keigo Yorozu; Mitsue Kurasawa; Daiko Wakita; Osamu Kondoh
Journal:  Cancer Diagn Progn       Date:  2022-09-03

5.  Sexuality in breast cancer survivors: sexual experiences, emotions, and cognitions in a group of women under hormonal therapy.

Authors:  F M Nimbi; S Magno; L Agostini; A Di Micco; C Maggiore; B M De Cesaris; R Rossi; R Galizia; C Simonelli; R Tambelli
Journal:  Breast Cancer       Date:  2022-01-06       Impact factor: 3.307

6.  Distant Metastasis after Surgery for Encapsulated Papillary Carcinoma of the Breast: A Case Report.

Authors:  Miyuki Kitahara; Yasuo Hozumi; Naoto Takeuchi; Satoko Ichinohe; Saori Fujiwara; Mitsuki Machinaga; Hitoaki Saitoh; Tatsuo Iijima
Journal:  Case Rep Oncol       Date:  2020-09-29

7.  A quality evaluation of the clinical practice guidelines on breast cancer using the RIGHT checklist.

Authors:  Hanqiong Zhou; Haiyang Chen; Cheng Cheng; Xuan Wu; Yanfang Ma; Jing Han; Ding Li; Geok Hoon Lim; Warren M Rozen; Naohiro Ishii; Pankaj G Roy; Qiming Wang
Journal:  Ann Transl Med       Date:  2021-07

8.  A Systematic Review and Quality Assessment of Breast Cancer Clinical Practice Guidelines Providing Complementary and Alternative Medicine Recommendations.

Authors:  Jeremy Y Ng; Hosna Sahak; Stephanie Ka Ching Lau
Journal:  Curr Oncol Rep       Date:  2021-08-03       Impact factor: 5.075

9.  Quality and reporting of clinical guidelines for breast cancer treatment: A systematic review.

Authors:  Marta Maes-Carballo; Luciano Mignini; Manuel Martín-Díaz; Aurora Bueno-Cavanillas; Khalid Saeed Khan
Journal:  Breast       Date:  2020-08-10       Impact factor: 4.380

Review 10.  Palbociclib as an early-line treatment for Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review of clinical trial and real-world data.

Authors:  Norikazu Masuda; Nobuyoshi Kosaka; Hiroji Iwata; Masakazu Toi
Journal:  Int J Clin Oncol       Date:  2021-10-26       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.